These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22993341)

  • 1. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.
    Endo J; Iihara H; Yamada M; Yanase K; Kamiya F; Ito F; Funaguchi N; Ohno Y; Minatoguchi S; Itoh Y
    Anticancer Res; 2012 Sep; 32(9):3939-47. PubMed ID: 22993341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
    Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption characteristics of azasetron from rectal and oral routes in rabbits.
    Moriyama Y; Arimori K; Nakano M
    Biol Pharm Bull; 1997 Jun; 20(6):701-3. PubMed ID: 9212995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.
    Ayuhara H; Takayanagi R; Okuyama K; Yoshimoto K; Ozeki T; Yokoyama H; Yamada Y
    Int J Clin Oncol; 2009 Dec; 14(6):518-24. PubMed ID: 19967488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
    Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
    Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats.
    Katayama K; Asano K; Haga K; Fukuda T
    Jpn J Pharmacol; 1997 Apr; 73(4):357-60. PubMed ID: 9165374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.
    Nakamura H; Yokoyama H; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Biol Pharm Bull; 2013; 36(5):780-7. PubMed ID: 23459393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
    Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.
    Gurpide A; Sadaba B; Martin-Algarra S; Azanza JR; Lopez-Picazo JM; Campanero MA; Cabello JP; Gil-Aldea I; de la Cruz S; Fernandez Gallego V; Reyna C; Olier Garate C; Blanco-Prieto MJ; Ceballos J; Garcia-Foncillas J; Perez-Gracia JL
    Oncologist; 2007 Sep; 12(9):1151-5. PubMed ID: 17914085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].
    Fujii M; Kanke M; Arai Y; Kawai S; Enomoto H; Inaba H; Taguchi T; Tsukuda M
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1557-63. PubMed ID: 11016001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
    Kimura E; Niimi S; Watanabe A; Akiyama M; Tanaka T
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):477-81. PubMed ID: 8678501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
    Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
    Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron.
    Sun L; Cun D; Yuan B; Cui H; Xi H; Mu L; Chen Y; Liu C; Wang Z; Fang L
    J Pharm Sci; 2012 Dec; 101(12):4540-8. PubMed ID: 22972714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1998 Oct; 71(1):113-5. PubMed ID: 9784330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.